A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors. The main objectives of this study are : To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ101 to show preliminary antitumor activity in patients with advanced solid tumors Participants will: Receive intravenous (IV) infusions of TJ101 at escalating dose levels (during dose escalation) or at the selected expansion dose. Undergo regular tumor imaging to assess response.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer (NSCLC)
- Prostate Cancer
- Esophageal Cancer
- Solid Tumor Malignancies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Phrontline Biopharma
- Last updated on ClinicalTrials.gov
- January 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Florida Cancer Specialists & Research Institute · Orlando, FL
Tennessee · 1
- Sarah Cannon Research Institute (SCRI) · Nashville, TN
Texas · 1
- Oncology Consultants · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.